ABCL•November 22, 2026 at 5:12 PM UTCPharmaceuticals, Biotechnology & Life Sciences

AbCellera Targets Mid-2027 Phase 3 for ABCL635, But Durability Proof Still Missing

Read source article

What happened

CEO Carl Hansen announced at a UBS conference that AbCellera is targeting a Phase 3 trial for its hot flash drug ABCL635 around mid-2027, while preparing further Phase 2 data and regulatory discussions. This aligns with the master report's expectation that management would provide explicit late-stage planning language by year-end 2026, but the announcement lacks concrete durability data or a formal trial protocol. The market already prices ABCL635 as a near-registrational asset following the strong week-4 Phase 2 results, so this update is incremental and does not resolve the key uncertainties. Financials remain weak with widening losses and heavy reliance on a single asset, and the company has yet to demonstrate sustained efficacy or clean long-term safety. Without week-12 follow-up or Phase 3 design details, the WAIT rating from the master report remains appropriate.

Implication

Investors should continue to hold and demand concrete evidence: week-12 efficacy and safety follow-up, along with a detailed Phase 3 protocol. The new Phase 3 timeline is a positive signaling step but does not de-risk the asset; the current valuation already assumes late-stage success, leaving little room for disappointment. If longer-duration data confirms the initial signal and the Phase 3 design mirrors successful comparator trials, the stock could move toward the bull scenario of $18. However, if data wanes or regulatory feedback delays the program, the stock could fall to the bear scenario of $9. Until those catalysts materialize, the risk-reward at $13.70 is not compelling enough to justify new positions, and existing shareholders should monitor year-end disclosures closely.

Thesis delta

The news provides a firmer Phase 3 timeline than previously disclosed but does not alter the core thesis. The master report already required explicit late-stage planning as a catalyst, and this announcement partially satisfies that requirement, but the missing durability data remains the critical variable. Therefore, the investment thesis remains unchanged at WAIT, with the same conviction level.

Confidence

high